Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections.
adherence
antiretroviral therapy
dried blood spots
pharmacokinetics
tenofovir diphosphate
Journal
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
ISSN: 1537-6591
Titre abrégé: Clin Infect Dis
Pays: United States
ID NLM: 9203213
Informations de publication
Date de publication:
08 04 2019
08 04 2019
Historique:
received:
11
05
2018
accepted:
21
08
2018
pubmed:
24
8
2018
medline:
26
6
2020
entrez:
24
8
2018
Statut:
ppublish
Résumé
Although tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is a predictor of adherence and pre-exposure prophylaxis efficacy, its utility in human immunodeficiency virus (HIV) treatment remains unknown. DBS for TFV-DP were collected up to 3 times over 48 weeks in persons living with HIV (PLWH) who were receiving TFV disoproxil fumarate (TDF)-based therapy. Log-transformed baseline TFV-DP was compared using t-tests or analyses of variance; generalized estimating equations were used to estimate the adjusted odds ratio (aOR) of viral suppression (<20 copies/mL) based on the TFV-DP concentration at the study visit. We analyzed 1199 DBS from 532 participants (76 female; 101 Black, 101 Hispanic). Among the virologically-suppressed participants at baseline (n = 347), TFV-DP was lower in Blacks (geometric mean 1453, 95% confidence interval [CI] 1291-1635) vs Whites (1793, 95% CI 1678-1916; P = .002) and Hispanics (1760, 95% CI 1563-1982; P = .025); in non-boosted (1610, 95% CI 1505-1723) vs. boosted (1888, 95% CI 1749-2037; P = .002) regimens; and in non-nucleoside reverse transcription inhibitor-based (1563, 95% CI 1432-1707) vs. boosted protease inhibitor-based (1890, 95% CI 1704-2095; P = .006) and multiclass-based (1927, 95% CI 1650-2252; P = .022) regimens. The aOR of virologic suppression, after adjusting for age, gender, race, body mass index, estimated glomerular filtration rate, CD4+ T-cell count, antiretroviral drug class and duration of therapy, was 73.5 (95% CI 25.7-210.5; P < .0001) for a TFV-DP concentration ≥1850 fmol/punch compared to <350 fmol/punch. TFV-DP in DBS is strongly associated with virologic suppression in PLWH on TDF-based therapy and is associated with certain participant characteristics. Further research is required to evaluate this drug adherence and exposure measure in clinical practice. NCT02012621.
Sections du résumé
BACKGROUND
Although tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is a predictor of adherence and pre-exposure prophylaxis efficacy, its utility in human immunodeficiency virus (HIV) treatment remains unknown.
METHODS
DBS for TFV-DP were collected up to 3 times over 48 weeks in persons living with HIV (PLWH) who were receiving TFV disoproxil fumarate (TDF)-based therapy. Log-transformed baseline TFV-DP was compared using t-tests or analyses of variance; generalized estimating equations were used to estimate the adjusted odds ratio (aOR) of viral suppression (<20 copies/mL) based on the TFV-DP concentration at the study visit.
RESULTS
We analyzed 1199 DBS from 532 participants (76 female; 101 Black, 101 Hispanic). Among the virologically-suppressed participants at baseline (n = 347), TFV-DP was lower in Blacks (geometric mean 1453, 95% confidence interval [CI] 1291-1635) vs Whites (1793, 95% CI 1678-1916; P = .002) and Hispanics (1760, 95% CI 1563-1982; P = .025); in non-boosted (1610, 95% CI 1505-1723) vs. boosted (1888, 95% CI 1749-2037; P = .002) regimens; and in non-nucleoside reverse transcription inhibitor-based (1563, 95% CI 1432-1707) vs. boosted protease inhibitor-based (1890, 95% CI 1704-2095; P = .006) and multiclass-based (1927, 95% CI 1650-2252; P = .022) regimens. The aOR of virologic suppression, after adjusting for age, gender, race, body mass index, estimated glomerular filtration rate, CD4+ T-cell count, antiretroviral drug class and duration of therapy, was 73.5 (95% CI 25.7-210.5; P < .0001) for a TFV-DP concentration ≥1850 fmol/punch compared to <350 fmol/punch.
CONCLUSIONS
TFV-DP in DBS is strongly associated with virologic suppression in PLWH on TDF-based therapy and is associated with certain participant characteristics. Further research is required to evaluate this drug adherence and exposure measure in clinical practice.
CLINICAL TRIALS REGISTRATION
NCT02012621.
Identifiants
pubmed: 30137238
pii: 5078212
doi: 10.1093/cid/ciy708
pmc: PMC6451996
doi:
Substances chimiques
Antiviral Agents
0
Organophosphates
0
tenofovir diphosphate
0
Adenine
JAC85A2161
Banques de données
ClinicalTrials.gov
['NCT02012621']
Types de publication
Journal Article
Observational Study
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1335-1342Subventions
Organisme : NIAID NIH HHS
ID : K23 AI104315
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI122298
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI124859
Pays : United States
Informations de copyright
© The Author(s) 2018. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
Références
Antimicrob Agents Chemother. 2009 May;53(5):1937-43
pubmed: 19273671
Antimicrob Agents Chemother. 2006 Oct;50(10):3297-304
pubmed: 17005808
AIDS. 2018 Jan 28;32(3):347-355
pubmed: 29194118
J Acquir Immune Defic Syndr. 2006 Aug 1;42(4):455-9
pubmed: 16810111
Infect Disord Drug Targets. 2011 Apr;11(2):167-74
pubmed: 21406048
J Acquir Immune Defic Syndr. 2006 Nov 1;43(3):278-83
pubmed: 17079992
AIDS. 2009 Jun 1;23(9):1035-46
pubmed: 19381075
Br J Clin Pharmacol. 2007 Nov;64(5):655-61
pubmed: 17610528
Lancet Infect Dis. 2014 Sep;14(9):820-9
pubmed: 25065857
JAMA Intern Med. 2016 Jan;176(1):75-84
pubmed: 26571482
AIDS Patient Care STDS. 2006 Sep;20(9):628-36
pubmed: 16987049
Am J Epidemiol. 2018 Sep 1;187(9):1990-2001
pubmed: 29767681
J Chromatogr B Analyt Technol Biomed Life Sci. 2006 Nov 7;843(2):147-56
pubmed: 16828350
AIDS. 2014 Jan 2;28(1):59-66
pubmed: 24275255
Expert Opin Drug Metab Toxicol. 2017 Jun;13(6):641-650
pubmed: 28335648
Curr HIV/AIDS Rep. 2018 Feb;15(1):49-59
pubmed: 29380227
J Acquir Immune Defic Syndr. 2017 Aug 15;75(5):548-553
pubmed: 28471841
J Pharm Biomed Anal. 2016 Apr 15;122:16-20
pubmed: 26829517
AIDS Res Hum Retroviruses. 2015 Apr;31(4):428-32
pubmed: 25328112
Epidemiology. 2018 Jan;29(1):67-75
pubmed: 29068838
AIDS Res Hum Retroviruses. 2013 Feb;29(2):384-90
pubmed: 22935078
Antimicrob Agents Chemother. 2017 Dec 21;62(1):
pubmed: 29038282
Antimicrob Agents Chemother. 2007 Jun;51(6):2105-11
pubmed: 17438052
Antimicrob Agents Chemother. 2013 Apr;57(4):1840-3
pubmed: 23380733
Antimicrob Agents Chemother. 2007 Oct;51(10):3498-504
pubmed: 17664327
HIV Clin Trials. 2004 Mar-Apr;5(2):74-9
pubmed: 15116282
Antiviral Res. 2016 Jan;125:63-70
pubmed: 26640223
J Infect Dis. 2018 Jun 20;218(2):234-238
pubmed: 29529230
J Acquir Immune Defic Syndr. 2017 Jan 1;74(1):21-29
pubmed: 27632233
Am J Epidemiol. 2009 Jan 1;169(1):113-21
pubmed: 18990716
HIV Clin Trials. 2007 Sep-Oct;8(5):282-92
pubmed: 17956829
AIDS. 2017 Oct 23;31(16):2245-2251
pubmed: 28832411
Clin Pharmacol Ther. 2008 Feb;83(2):265-72
pubmed: 17597712
PLoS One. 2013 Dec 02;8(12):e80242
pubmed: 24312465
Curr Opin HIV AIDS. 2017 Sep;12(5):467-474
pubmed: 28590335
Clin Infect Dis. 2002 Apr 15;34(8):1115-21
pubmed: 11915001
J Acquir Immune Defic Syndr. 2018 Feb 1;77(2):193-198
pubmed: 28991887
J Acquir Immune Defic Syndr. 2018 Jan 1;77(1):86-92
pubmed: 28961682
AIDS. 2015 Jun 1;29(9):1113-5
pubmed: 25870991